Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Arq. neuropsiquiatr ; 56(2): 171-5, jun. 1998. tab
Article in English | LILACS | ID: lil-212805

ABSTRACT

Objective: The aim of the present study is to investigate whether there are geographic differences in the etiology of parkinsonism (PA). Background: 72 percent of patients with PA evaluated at movement disorders clinics in the Northern Hemisphere are diagnosed with Parkinson's disease (PD). Data regarding other regions are not available. Methods: We reviewed the charts of all patients with PA seen at the Federal University of Minas Gerais Movement Disorders Clinic from July 1993 through October 1995. PA was diagnosed by the presence of at least two of the following: rest tremor, bradykinesia, rigidity, and postural instability. The different etiologies were diagnosed based on standard clinical criteria Results: During the period of the study, PA was recognized in 338 subjects. The following clinical diagnoses were made: PD (68.9 percent), drug-induced PA (DIP) (13,3 percent), vascular PA (4.7 percent), progressive supranuclear palsy (PSP) (2 percent), multiple system atrophy (MSA) (1.8 percent), others (9.7 percent). Cinnarizine, haloperidol and flunarizine were the commonest drugs related to DIP. Conclusions: Similarly to other studies, PD accounts for about 70 percent of PA patients. However, there are differences between our results and previous series. DIP is much more common in the present series. This may be accounted for a more liberal use of antidopaminergic drugs in our environment, especially Calcium channel blockers. The lower frequency of MSA and PSP in our study may reflect a short follow-up, since many patients initially diagnosed with PD later are found to have Parkinson-plus syndromes.


Subject(s)
Humans , Male , Female , Middle Aged , Parkinson Disease, Secondary/etiology , Anti-Dyskinesia Agents/adverse effects , Brazil , Calcium Channel Blockers/adverse effects , Cinnarizine/adverse effects , Flunarizine/adverse effects , Haloperidol/adverse effects , Histamine H1 Antagonists/adverse effects , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/diagnosis , Parkinson Disease/complications , Parkinson Disease/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL